Eli Lilly and CoXSWX:LLY 100 Days Payable is 133.59 as of Mar. 2026, which is 32% above its 10-year median of 101.52. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,111.74 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Eli Lilly and Co ranks better than 69.12% on this metric.
The historical rank and industry rank for Eli Lilly and Co's Days Payable or its related term are showing as below:
XSWX:LLY'
s Days Payable Range Over the Past 10 Years
Min: 81.79 Med: 101.52 Max: 142.14
Current: 130.57
During the past 13 years, Eli Lilly and Co's highest Days Payable was 142.14. The lowest was 81.79. And the median was 101.52.
XSWX:LLY's Days Payable is ranked better than 69.12% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs XSWX:LLY: 130.57
Eli Lilly and Co's Days Payable
declined
from Mar. 2025 (137.39) to Mar. 2026 (133.59).
It may suggest that Eli Lilly and Coaccelerated paying its suppliers.
Eli Lilly and Co Days Payable Related Terms
Eli Lilly and Co Days Payable Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LLY vs JNJ, ABBV, MRK: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Eli Lilly and Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a Days Payable of 133.59 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eli Lilly and Co and its competitors. This is 32% above median its historical median of 101.52. Over the past decade, Eli Lilly and Co's Days Payable has ranged from 81.79 to 142.14. According to the industry distribution chart, Eli Lilly and Co ranks #285 out of 923 companies in the Drug Manufacturers industry, placing it in the top 30.9%.
Is Eli Lilly and Co's Days Payable too high?
Eli Lilly and Co's current Days Payable of 133.59 is 32% above median its 10-year median of 101.52. Over the past 10 years, this metric has ranged from a low of 81.79 to a high of 142.14. The Drug Manufacturers industry median Days Payable is 90.98. Eli Lilly and Co's value of 133.59 is 46.8% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #285 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Days Payable compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #285 out of 923 companies for Days Payable. This puts Eli Lilly and Co in the upper half of its industry. The industry median Days Payable is 90.98. Eli Lilly and Co's value of 133.59 is 46.8% above this benchmark. Historically, Eli Lilly and Co's own Days Payable has ranged from 81.79 to 142.14 over the past decade. While the company's 10-year median is 101.52 vs. the industry median of 90.98, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Days Payable of 133.59 is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Days Payable is 133.59, which is 32% above median its own 10-year median of 101.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,111.74, compared to a current price of CHF915.00 — trading 17.7% below its estimated fair value. The current Days Payable is 133.59, which is 32% above median its 10-year median of 101.52 and 46.8% above the Drug Manufacturers industry median of 90.98. Eli Lilly and Co's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Days Payable is 133.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF915.00 is trading 17.7% below its estimated GF Value™ of CHF1,111.74.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Days Payable: 133.59 (32% above median its 10-year median of 101.52)
GF Value™: CHF1,111.74 vs. price of CHF915.00 (17.7% below fair value)
Industry Position: 46.8% above the Drug Manufacturers median (#285 of 923)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
